Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of "Buy" by Analysts

Key Points

• Analysts have assigned Ascendis Pharma A/S a consensus rating of "Buy", with fifteen ratings firms covering the stock.
• The average 12-month target price for Ascendis Pharma is $243.36, with some analysts raising their targets significantly, including Citigroup's increase to $290.00.
• In its latest quarterly earnings report, Ascendis Pharma exceeded expectations by posting a revenue of $216.28 million against an anticipated $163.17 million.

Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have been assigned an average recommendation of "Buy" from the fifteen ratings firms that are covering the firm, Marketbeat.com reports. Fifteen analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $243.3571.

ASND has been the topic of a number of recent analyst reports. Evercore ISI increased their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. Stifel Nicolaus increased their price target on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Wall Street Zen raised shares of Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Wedbush upped their price objective on shares of Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Finally, Citigroup restated a "buy" rating and issued a $290.00 price objective (up from $243.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ASND. Perceptive Advisors LLC bought a new position in shares of Ascendis Pharma A/S in the second quarter worth approximately $166,367,000. T. Rowe Price Investment Management Inc. lifted its stake in Ascendis Pharma A/S by 54.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company's stock worth $375,226,000 after acquiring an additional 960,504 shares during the period. RA Capital Management L.P. lifted its stake in Ascendis Pharma A/S by 4.1% in the fourth quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after acquiring an additional 402,316 shares during the period. Adage Capital Partners GP L.L.C. purchased a new stake in Ascendis Pharma A/S in the first quarter worth $51,029,000. Finally, Vestal Point Capital LP lifted its stake in Ascendis Pharma A/S by 108.0% in the fourth quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company's stock worth $71,588,000 after acquiring an additional 270,000 shares during the period.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $192.80 on Friday. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $199.99. The firm has a market cap of $11.80 billion, a price-to-earnings ratio of -37.36 and a beta of 0.41. The company has a fifty day moving average price of $177.73 and a 200-day moving average price of $162.97.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping analysts' consensus estimates of ($1.42) by $0.49. The company had revenue of $216.28 million during the quarter, compared to analysts' expectations of $163.17 million. On average, research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.